Gallium-68-Labeled Anti-HER2 Single-Chain Fv Fragment: Development and In Vivo Monitoring of HER2 Expression

Synthesis and evaluation of a radioiodinated peptide probe targeting αvβ6 integrin for the detection of pancreatic ductal adenocarcinoma

(2014) Masashi Ueda et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Trastuzumab for patients with HER2 positive breast cancer: Delivery, duration and combination therapies

(2013) Ana Catarina Pinto et al.   BREAST

Miniaturized antibodies for imaging membrane type-1 matrix metalloproteinase in cancers

(2013) Naoya Kondo et al.   CANCER SCIENCE

64Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer

(2013) K. Tamura et al.   JOURNAL OF NUCLEAR MEDICINE

Inhibition of HSP90 molecular chaperones: moving into the clinic

(2013) Rocio Garcia-Carbonero et al.   LANCET ONCOLOGY

Development of an Oxygen-Sensitive Degradable Peptide Probe for the Imaging of Hypoxia-Inducible Factor-1-Active Regions in Tumors

(2013) Masashi Ueda et al.   MOLECULAR IMAGING AND BIOLOGY

Micelle-based activatable probe for in vivo near-infrared optical imaging of cancer biomolecules

(2013) Yoichi Shimizu et al.   Nanomedicine-Nanotechnology Biology and Medicine

Evaluation of backbone-cyclized HER2-binding 2-helix Affibody molecule for In Vivo molecular imaging

(2013) Hadis Honarvar et al.   NUCLEAR MEDICINE AND BIOLOGY

Development of Novel 123I-Labeled Pyridyl Benzofuran Derivatives for SPECT Imaging of β-Amyloid Plaques in Alzheimer’s Disease

(2013) Masahiro Ono et al.   PLoS One

HER2 Status in Gastric and Gastroesophageal Junction Cancer Assessed by Local and Central Laboratories: Chinese Results of the HER-EAGLE Study

(2013) Dan Huang et al.   PLoS One

Her2/neu testing in gastric cancer: evaluating the risk of sampling errors

(2012) V. S. Warneke et al.   ANNALS OF ONCOLOGY

Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors

(2012) Dorte L. Nielsen et al.   BREAST

A Phase I Dose-Escalation Trial of Trastuzumab and Alvespimycin Hydrochloride (KOS-1022; 17 DMAG) in the Treatment of Advanced Solid Tumors

(2012) K. Jhaveri et al.   CLINICAL CANCER RESEARCH

Feasibility and availability of 68Ga-labelled peptides

(2012) Clemens Decristoforo et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Accumulation of arginine-rich cell-penetrating peptides in tumors and the potential for anticancer drug delivery in vivo

(2012) Ikuhiko Nakase et al.   JOURNAL OF CONTROLLED RELEASE

Potential of PET to Predict the Response to Trastuzumab Treatment in an ErbB2-Positive Human Xenograft Tumor Model

(2012) G. Kramer-Marek et al.   JOURNAL OF NUCLEAR MEDICINE

Immuno-PET of the Hepatocyte Growth Factor Receptor Met Using the 1-Armed Antibody Onartuzumab

(2012) E. M. Jagoda et al.   JOURNAL OF NUCLEAR MEDICINE

RGD conjugates of the H2dedpa scaffold: synthesis, labeling and imaging with 68Ga

(2012) Eszter Boros et al.   NUCLEAR MEDICINE AND BIOLOGY

Improving Treatment of HER2-Positive Cancers: Opportunities and Challenges

(2012) H. M. Stern   Science Translational Medicine

Uptake and release of metal ions by transferrin and interaction with receptor 1

(2011) Jean-Michel El Hage Chahine et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers

(2011) Naomi Ono et al.   CANCER SCIENCE

HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care

(2011) A. Fabi et al.   CLINICAL CANCER RESEARCH

Facile labelling of an anti-epidermal growth factor receptor Nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET

(2011) Maria J. W. D. Vosjan et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes-A systematic review

(2011) Terence C. Chua et al.   INTERNATIONAL JOURNAL OF CANCER

Evaluation of the Anti-HER2 C6.5 Diabody as a PET Radiotracer to Monitor HER2 status and Predict Response to Trastuzumab Treatment

(2010) Smitha Reddy et al.   CLINICAL CANCER RESEARCH

Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer

(2010) E C Dijkers et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Molecular imaging of HER2-positive breast cancer: a step toward an individualized ‘image and treat’ strategy

(2010) Jacek Capala et al.   CURRENT OPINION IN ONCOLOGY

A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue

(2010) Vladimir Tolmachev et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules

(2010) R. P. Baum et al.   JOURNAL OF NUCLEAR MEDICINE

PET Imaging of Hypoxia-Inducible Factor-1-Active Tumor Cells with Pretargeted Oxygen-Dependent Degradable Streptavidin and a Novel 18F-Labeled Biotin Derivative

(2010) Takashi Kudo et al.   MOLECULAR IMAGING AND BIOLOGY

HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy

(2009) Jessica N McAlpine et al.   BMC CANCER

Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations

(2009) Guido Sauter et al.   JOURNAL OF CLINICAL ONCOLOGY

A 2-Helix Small Protein Labeled with 68Ga for PET Imaging of HER2 Expression

(2009) G. Ren et al.   JOURNAL OF NUCLEAR MEDICINE

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth

(2009) S Chandarlapaty et al.   ONCOGENE